

# Manuel Alfonso Patarroyo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11915857/publications.pdf>

Version: 2024-02-01

29  
papers

588  
citations

623734

14  
h-index

610901

24  
g-index

29  
all docs

29  
docs citations

29  
times ranked

620  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cervical cancer screening programme attendance and compliance predictors regarding Colombia's Amazon region. <i>PLoS ONE</i> , 2022, 17, e0262069.	2.5	0
2	T Cell Peptides Derived from Invasive Stages of <i>Schistosoma mansoni</i> as Potential Schistosomiasis Vaccine. <i>Journal of Clinical Medicine</i> , 2021, 10, 445.	2.4	1
3	<i>Mycobacterium tuberculosis</i> Rv0292 Protein Peptides Could be Included in a Synthetic Anti-tuberculosis Vaccine. <i>International Journal of Peptide Research and Therapeutics</i> , 2021, 27, 2823.	1.9	1
4	Hotspots in Plasmodium and RBC Receptor-Ligand Interactions: Key Pieces for Inhibiting Malarial Parasite Invasion. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4729.	4.1	11
5	From a basic to a functional approach for developing a blood stage vaccine against <i>Plasmodium vivax</i> . <i>Expert Review of Vaccines</i> , 2020, 19, 195-207.	4.4	4
6	Major Histocompatibility Complex Class II (DRB3) Genetic Diversity in Spanish Morucha and Colombian Normande Cattle Compared to Taurine and Zebu Populations. <i>Frontiers in Genetics</i> , 2020, 10, 1293.	2.3	16
7	<i>Plasmodium falciparum</i> pre-erythrocytic stage vaccine development. <i>Malaria Journal</i> , 2020, 19, 56.	2.3	36
8	Specific Binding Peptides from Rv3632: A Strategy for Blocking <i>Mycobacterium tuberculosis</i> Entry to Target Cells?. <i>BioMed Research International</i> , 2019, 2019, 1-13.	1.9	3
9	<i>Plasmodium falciparum</i> Blood Stage Antimalarial Vaccines: An Analysis of Ongoing Clinical Trials and New Perspectives Related to Synthetic Vaccines. <i>Frontiers in Microbiology</i> , 2019, 10, 2712.	3.5	17
10	Towards designing a synthetic antituberculosis vaccine: The Rv3587c peptide inhibits mycobacterial entry to host cells. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 2401-2409.	3.0	13
11	<i>Plasmodium vivax</i> Pv12 B-cell epitopes and HLA-DR $\beta$ 1*-dependent T-cell epitopes in vitro antigenicity. <i>PLoS ONE</i> , 2018, 13, e0203715.	2.5	3
12	<i>Mycobacterium tuberculosis</i> H37Rv LpqG Protein Peptides Can Inhibit Mycobacterial Entry through Specific Interactions. <i>Molecules</i> , 2018, 23, 526.	3.8	5
13	Association of HIV status with infection by multiple HPV types. <i>Tropical Medicine and International Health</i> , 2018, 23, 1259-1268.	2.3	15
14	Structural analysis of owl monkey MHC-DR shows that fully-protective malaria vaccine components can be readily used in humans. <i>Biochemical and Biophysical Research Communications</i> , 2017, 491, 1062-1069.	2.1	20
15	The Prevalence of High-Risk HPV Types and Factors Determining Infection in Female Colombian Adolescents. <i>PLoS ONE</i> , 2016, 11, e0166502.	2.5	14
16	Cell-Peptide Specific Interaction Can Inhibit <i>Mycobacterium tuberculosis</i> H37Rv Infection. <i>Journal of Cellular Biochemistry</i> , 2016, 117, 946-958.	2.6	6
17	IMPIPS: The Immune Protection-Inducing Protein Structure Concept in the Search for Steric-Electron and Topochemical Principles for Complete Fully-Protective Chemically Synthesised Vaccine Development. <i>PLoS ONE</i> , 2015, 10, e0123249.	2.5	25
18	The DNA load of six high-risk human papillomavirus types and its association with cervical lesions. <i>BMC Cancer</i> , 2015, 15, 100.	2.6	36

#	ARTICLE	IF	CITATIONS
19	Mce4F Mycobacterium tuberculosis protein peptides can inhibit invasion of human cell lines. Pathogens and Disease, 2015, 73, .	2.0	17
20	Human papillomavirus detection in women with and without human immunodeficiency virus infection in Colombia. BMC Cancer, 2014, 14, 451.	2.6	14
21	Rv1268c protein peptide inhibiting Mycobacterium tuberculosis H37Rv entry to target cells. Bioorganic and Medicinal Chemistry, 2013, 21, 6650-6656.	3.0	6
22	Structural and Immunological Principles Leading to Chemically Synthesized, Multiantigenic, Multistage, Minimal Subunit-Based Vaccine Development. Chemical Reviews, 2011, 111, 3459-3507.	47.7	93
23	Detection by PCR of human papillomavirus in Colombia: Comparison of GP5+/6+ and MY09/11 primer sets. Journal of Virological Methods, 2011, 178, 68-74.	2.1	35
24	Distribution Patterns of Infection with Multiple Types of Human Papillomaviruses and Their Association with Risk Factors. PLoS ONE, 2011, 6, e14705.	2.5	42
25	Synthetic vaccine update: Applying lessons learned from recent SPf66 malarial vaccine physicochemical, structural and immunological characterization. Vaccine, 2007, 25, 4487-4501.	3.8	15
26	Functional, structural, and immunological compartmentalisation of malaria invasive proteins. Biochemical and Biophysical Research Communications, 2007, 354, 363-371.	2.1	22
27	A pre-PEXEL histidine-rich protein II erythrocyte binding peptide as a new way for anti-malarial vaccine development. Biochemical and Biophysical Research Communications, 2007, 360, 149-155.	2.1	5
28	A highly infective Plasmodium vivax strain adapted to Aotus monkeys: Quantitative haematological and molecular determinations useful for P. vivax malaria vaccine development. Vaccine, 2003, 21, 3930-3937.	3.8	38
29	Genetic polymorphism of the Duffy receptor binding domain of Plasmodium vivax in Colombian wild isolates. Molecular and Biochemical Parasitology, 1996, 78, 269-272.	1.1	75